Advertisement
ALNY vs ZTS
Which Stock Would AI Choose? Alnylam Pharmaceuticals (ALNY) vs. Zoetis (ZTS) Stock Comparison
Key Takeaways
- ALNY has demonstrated robust revenue growth, with nearly $3 billion in 2025 net product revenues, driven by a 151% surge in its TTR franchise, contrasting ZTS's more modest recent performance amid companion animal market softness.
- Year-to-date, ALNY shows mixed momentum with recent weekly declines but stronger longer-term gains of about 30% over one year, while ZTS faces pressure with YTD declines around 8% and 27% over one year.
- Both stocks trade at potential discounts to fair value estimates—ALNY around 34-49% undervalued and ZTS about 20-33%—highlighting relative value in healthcare sectors.
- ALNY benefits from RNAi innovation and pipeline expansion like AMVUTTRA approvals, while ZTS leverages stable animal health demand but contends with competition and macro trends.
- Market sentiment favors ALNY's growth trajectory in biotech over ZTS's defensive positioning in veterinary care during recent volatility.
Introduction
This stock comparison between Alnylam Pharmaceuticals (ALNY) and Zoetis (ZTS) examines two healthcare leaders navigating distinct market dynamics. ALNY, a biotech innovator in RNAi therapeutics, contrasts with ZTS, the dominant player in animal health. Traders seeking high-growth biotech exposure with pipeline catalysts may eye ALNY, while investors prioritizing defensive stability in veterinary products might prefer ZTS. Amid broader sector rotation and economic pressures, this analysis highlights relative performance, growth drivers, and positioning for informed stock comparison decisions.
ALNY Overview and Recent Performance
Alnylam Pharmaceuticals (ALNY) pioneers RNA interference (RNAi) therapeutics, focusing on rare and prevalent diseases through drugs like AMVUTTRA and ONPATTRO for ATTR amyloidosis. The company reported nearly $3 billion in 2025 global net product revenues, up 81% year-over-year, with TTR franchise growth exceeding 150%. Recent market activity shows shares around $313-$317, down about 1-2% weekly and 3% monthly, reflecting biotech volatility, yet up 30% over one year. Sentiment has been influenced by strong Q4 results, AMVUTTRA approvals for ATTR-CM, and the "Alnylam 2030" strategy targeting 25%+ revenue CAGR. Pipeline advancements, including Phase 3 trials and manufacturing innovations, bolster long-term positioning despite YTD declines near 21% amid sector pressures.
ZTS Overview and Recent Performance
Zoetis (ZTS), the world's leading animal health company, develops medicines, vaccines, and diagnostics for companion animals and livestock across categories like dermatology and oncology. Recent performance reflects challenges, with shares trading near $116-$117, down 3-5% weekly, 8% monthly, 8% YTD, and 27% over one year, pressured by U.S. companion animal softness and competition. Macro trends, including reduced veterinary visits, have tempered growth, though the company projects $9.5 billion in 2025 revenue. Positive factors include a robust R&D pipeline in chronic kidney disease and cardiology, representing over $5 billion in opportunities, alongside innovation in areas like Librela. Analysts note undervaluation and recovery potential despite regulatory and competitive risks.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top performers from hundreds of AI trading bots that analyze thousands of tickers using advanced machine learning. Only the most promising bots, suited to current volatile market conditions like sector rotations in energy, semiconductors, and aerospace, earn a spot in this dynamic section. These bots showcase impressive stats: annualized returns ranging from 17% to over 200%, win rates of 53% to 95%, profit factors up to 25.83, and trading 1 to 25 tickers across timeframes from 5 minutes to 60 minutes. Styles vary from trend-following and dip-buying to hedging with leveraged ETFs. Explore these high-performing AI agents to enhance your trading edge in today’s market.
Head-to-Head Comparison
ALNY and ZTS operate in healthcare but diverge sharply: ALNY’s biotech model drives explosive growth via RNAi innovation and TTR dominance, while ZTS offers steady veterinary demand with diversified livestock/companion exposure. Growth drivers contrast—ALNY’s 81% revenue surge and 25% CAGR goal versus ZTS’s 3-5% outlook amid macro headwinds. Recent momentum favors ALNY’s 30% one-year gain over ZTS’s 27% decline. Risks include ALNY’s clinical/regulatory hurdles and volatility versus ZTS’s competition and pet spending sensitivity. Sentiment leans toward ALNY’s catalysts in a risk-on environment, trading off ZTS’s stability for higher upside potential.
Tickeron AI Verdict
Tickeron’s AI currently favors ALNY due to superior trend consistency in revenue growth, emerging profitability, and pipeline catalysts like AMVUTTRA expansion, positioning it strongly amid biotech recovery signals. While ZTS offers relative stability, its recent momentum lags, making ALNY the probabilistic edge for growth-oriented relative performance in the current environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALNY is a Hold and ZTS is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALNY’s FA Score shows that 1 FA rating(s) are green whileZTS’s FA Score has 2 green FA rating(s).
- ALNY’s FA Score: 1 green, 4 red.
- ZTS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALNY’s TA Score shows that 3 TA indicator(s) are bullish while ZTS’s TA Score has 4 bullish TA indicator(s).
- ALNY’s TA Score: 3 bullish, 5 bearish.
- ZTS’s TA Score: 4 bullish, 6 bearish.
Price Growth
ALNY (@Biotechnology) experienced а +1.02% price change this week, while ZTS (@Pharmaceuticals: Generic) price change was -0.07% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.04%. For the same industry, the average monthly price growth was -3.95%, and the average quarterly price growth was +5.21%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.18%. For the same industry, the average monthly price growth was +3.88%, and the average quarterly price growth was -0.58%.
Reported Earning Dates
ALNY is expected to report earnings on Apr 30, 2026.
ZTS is expected to report earnings on May 07, 2026.
Industries' Descriptions
@Biotechnology (+1.04% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Generic (+3.18% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| ALNY | ZTS | ALNY / ZTS | |
| Capitalization | 43B | 49.6B | 87% |
| EBITDA | 631M | 4.07B | 16% |
| Gain YTD | -18.997 | -5.926 | 321% |
| P/E Ratio | 138.24 | 19.58 | 706% |
| Revenue | 3.71B | 9.47B | 39% |
| Total Cash | 2.91B | 2.31B | 126% |
| Total Debt | 1.28B | 9.24B | 14% |
ALNY | ZTS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 66 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 29 Undervalued | |
PROFIT vs RISK RATING 1..100 | 50 | 100 | |
SMR RATING 1..100 | 15 | 16 | |
PRICE GROWTH RATING 1..100 | 62 | 61 | |
P/E GROWTH RATING 1..100 | 100 | 86 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ZTS's Valuation (29) in the Pharmaceuticals Generic industry is somewhat better than the same rating for ALNY (94) in the Biotechnology industry. This means that ZTS’s stock grew somewhat faster than ALNY’s over the last 12 months.
ALNY's Profit vs Risk Rating (50) in the Biotechnology industry is somewhat better than the same rating for ZTS (100) in the Pharmaceuticals Generic industry. This means that ALNY’s stock grew somewhat faster than ZTS’s over the last 12 months.
ALNY's SMR Rating (15) in the Biotechnology industry is in the same range as ZTS (16) in the Pharmaceuticals Generic industry. This means that ALNY’s stock grew similarly to ZTS’s over the last 12 months.
ZTS's Price Growth Rating (61) in the Pharmaceuticals Generic industry is in the same range as ALNY (62) in the Biotechnology industry. This means that ZTS’s stock grew similarly to ALNY’s over the last 12 months.
ZTS's P/E Growth Rating (86) in the Pharmaceuticals Generic industry is in the same range as ALNY (100) in the Biotechnology industry. This means that ZTS’s stock grew similarly to ALNY’s over the last 12 months.
| ALNY | ZTS | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 55% |
| Stochastic ODDS (%) | 2 days ago 59% | 2 days ago 68% |
| Momentum ODDS (%) | 2 days ago 66% | 2 days ago 54% |
| MACD ODDS (%) | 2 days ago 68% | 2 days ago 65% |
| TrendWeek ODDS (%) | 2 days ago 71% | 2 days ago 61% |
| TrendMonth ODDS (%) | 2 days ago 69% | 2 days ago 63% |
| Advances ODDS (%) | 18 days ago 76% | 3 days ago 52% |
| Declines ODDS (%) | 10 days ago 66% | 16 days ago 58% |
| BollingerBands ODDS (%) | 2 days ago 73% | 2 days ago 62% |
| Aroon ODDS (%) | 2 days ago 78% | 2 days ago 65% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GMEU | 10.30 | 0.33 | +3.31% |
| T-Rex 2X Long GME Daily Target ETF | |||
| IBIG | 26.27 | N/A | -0.01% |
| iShares iBonds Oct 2030 Term Tips ETF | |||
| IJS | 122.88 | -0.37 | -0.30% |
| iShares S&P Small-Cap 600 Value ETF | |||
| HYBL | 27.85 | -0.09 | -0.32% |
| State Street® Blackstone High Income ETF | |||
| AAPX | 26.70 | -0.11 | -0.41% |
| T-Rex 2X Long Apple Daily Target ETF | |||
ZTS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with ELAN. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then ELAN could also see price increases.
| Ticker / NAME | Correlation To ZTS | 1D Price Change % | ||
|---|---|---|---|---|
| ZTS | 100% | -1.78% | ||
| ELAN - ZTS | 52% Loosely correlated | -1.41% | ||
| VTRS - ZTS | 44% Loosely correlated | -1.03% | ||
| PRGO - ZTS | 41% Loosely correlated | +2.45% | ||
| HLN - ZTS | 40% Loosely correlated | -0.40% | ||
| PAHC - ZTS | 39% Loosely correlated | -2.03% | ||
More | ||||